Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 310628, 16 pages
http://dx.doi.org/10.1155/2013/310628
Review Article

Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis

1West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
2Department of Rheumatology and Immunology, The First People’s Hospital of Yibin, Yibin, Sichuan 644000, China
3Department of Otolaryngology, The First People’s Hospital of Yibin, Yibin, Sichuan 644000, China
4The Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
5Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China

Received 1 May 2013; Revised 15 September 2013; Accepted 18 September 2013

Academic Editor: Xuan Zhang

Copyright © 2013 Jiangtao Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. R. O'Dell, “Rheumatoid arthritis,” in Goldman's Cecil Medicine, L. Goldman and A. I. Schafer, Eds., chapter 272, pp. 1681–1689, Elsevier/Saunders, 24th edition, 2012. View at Google Scholar
  2. L. J. Lü, J. L. Teng, C. D. Bao et al., “Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial,” Chinese Medical Journal, vol. 121, no. 7, pp. 615–619, 2008. View at Google Scholar · View at Scopus
  3. World Health Organization, “Good health adds life to years global brief for World Health Day 2012,” WHO Document Production Services, WHO, Geneva, Switzerland, 2012. View at Google Scholar
  4. F. Du, L. J. Lü, Q. Fu et al., “T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis,” Arthritis Research and Therapy, vol. 10, no. 6, article R136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Kohno, Y. Aikawa, Y. Tsubouchi et al., “Inhibitory effect of T-614 on tumor necrosis factor-α induced cytokine production and nuclear factor-κB activation in cultured human synovial cells,” Journal of Rheumatology, vol. 28, no. 12, pp. 2591–2596, 2001. View at Google Scholar · View at Scopus
  6. K. Tanaka, T. Yamamoto, Y. Aikawa et al., “Inhibitory effects of anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice,” Rheumatology, vol. 42, no. 11, pp. 1365–1371, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Du, L. J. Lü, J. L. Teng, N. Shen, P. Ye, and C. D. Bao, “T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro,” International Immunopharmacology, vol. 13, no. 1, pp. 54–60, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. “OMERACT conference on outcome measures in rheumatoid arthritis clinical trials,” Journal of Rheumatology, vol. 20, no. 3, pp. 526–591, 1993.
  9. D. T. Felson, J. J. Anderson, M. Boers et al., “American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 38, no. 6, pp. 727–735, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. A. M. van Gestel, M. L. L. Prevoo, M. A. Van 'T Hof, M. H. Van Rijswijk, L. B. A. Van De Putte, and P. L. C. M. Van Riel, “Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis,” Arthritis and Rheumatism, vol. 39, no. 1, pp. 34–40, 1996. View at Google Scholar · View at Scopus
  11. International Conference on Harmonisation Expert Working Group, “International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice,” in 1997 CFR & ICH Guidelines, Barnett International/PAREXEL, Philadelphia, Pa, USA, 1997. View at Google Scholar
  12. J. P. T. Higgins, D. G. Altman, and J. A. C. Sterne, “Assessing risk of bias in included studies,” in Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, J. P. T. Higgins and S. Green, Eds., Chapter 8, The Cochrane Collaboration, 2011, http://handbook.cochrane.org/. View at Google Scholar
  13. H. Schünemann, J. Brożek, and A. Oxman, GRADE Handbook for Grading Quality of Evidence and Strength of Recommendation, version 3.2, The GRADE Working Group, 2009, http://www.cc-ims.net/gradepro.
  14. L. J. Lu, C. D. Bao, M. Dai et al., “Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate,” Arthritis Care and Research, vol. 61, no. 7, pp. 979–987, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Hara, T. Abe, S. Sugawara et al., “Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study,” Modern Rheumatology, vol. 17, no. 1, pp. 1–9, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Ishiguro, K. Yamamoto, K. Katayama et al., “Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial,” Modern Rheumatology, vol. 23, no. 3, pp. 430–439, 2013. View at Publisher · View at Google Scholar
  17. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Google Scholar · View at Scopus
  18. M. C. Hochberg, R. W. Chang, I. Dwosh, S. Lindsey, T. Pincus, and F. Wolfe, “The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 35, no. 5, pp. 498–502, 1992. View at Google Scholar · View at Scopus
  19. M. Hara, T. Abe, S. Sugawara et al., “Long-term safety study of iguratimod in patients with rheumatoid arthritis,” Modern Rheumatology, vol. 17, no. 1, pp. 10–16, 2007. View at Publisher · View at Google Scholar · View at Scopus